全文获取类型
收费全文 | 4950212篇 |
免费 | 389641篇 |
国内免费 | 15682篇 |
专业分类
耳鼻咽喉 | 69378篇 |
儿科学 | 158476篇 |
妇产科学 | 130513篇 |
基础医学 | 742961篇 |
口腔科学 | 137919篇 |
临床医学 | 455388篇 |
内科学 | 905665篇 |
皮肤病学 | 117543篇 |
神经病学 | 414764篇 |
特种医学 | 193737篇 |
外国民族医学 | 968篇 |
外科学 | 742820篇 |
综合类 | 139090篇 |
现状与发展 | 24篇 |
一般理论 | 2811篇 |
预防医学 | 414256篇 |
眼科学 | 116024篇 |
药学 | 352672篇 |
26篇 | |
中国医学 | 13058篇 |
肿瘤学 | 247442篇 |
出版年
2021年 | 57343篇 |
2019年 | 59758篇 |
2018年 | 76653篇 |
2017年 | 58706篇 |
2016年 | 65058篇 |
2015年 | 77556篇 |
2014年 | 112216篇 |
2013年 | 177979篇 |
2012年 | 141589篇 |
2011年 | 149568篇 |
2010年 | 131620篇 |
2009年 | 131515篇 |
2008年 | 134656篇 |
2007年 | 144608篇 |
2006年 | 151981篇 |
2005年 | 146102篇 |
2004年 | 146833篇 |
2003年 | 136656篇 |
2002年 | 125210篇 |
2001年 | 197291篇 |
2000年 | 194250篇 |
1999年 | 174343篇 |
1998年 | 75919篇 |
1997年 | 70630篇 |
1996年 | 68802篇 |
1995年 | 64379篇 |
1994年 | 58211篇 |
1993年 | 54024篇 |
1992年 | 128588篇 |
1991年 | 123390篇 |
1990年 | 118838篇 |
1989年 | 115377篇 |
1988年 | 106268篇 |
1987年 | 104320篇 |
1986年 | 98421篇 |
1985年 | 95829篇 |
1984年 | 77790篇 |
1983年 | 68465篇 |
1982年 | 51635篇 |
1981年 | 47720篇 |
1980年 | 44742篇 |
1979年 | 67692篇 |
1978年 | 53052篇 |
1977年 | 46614篇 |
1976年 | 43247篇 |
1975年 | 44068篇 |
1974年 | 49000篇 |
1973年 | 46936篇 |
1972年 | 43932篇 |
1971年 | 40618篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
J.J. Crowley R.B. Warren J.C. Cather 《Journal of the European Academy of Dermatology and Venereology》2019,33(9):1676-1684
Psoriasis is a chronic disease that requires long‐term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)‐23. This article reviews published data on the safety of these IL‐23p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo‐ and active‐controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk–benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these IL‐23p19 inhibitors in the data published to date. The most commonly reported adverse events (AEs) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous Candida infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting IL‐23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long‐term extension studies and patient registries will further establish the safety profile of IL‐23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice. 相似文献
992.
Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an individual’s life and on society. Thus, developing more effective therapeutic interventions is essential. Over the past quarter‐century, an abundance of evidence from pharmacologic challenges, post‐mortem studies, brain imaging, and genetic studies supports the role of glutamatergic dysregulation in the pathophysiology of schizophrenia, and the results of recent randomized clinical trials based on this evidence have yielded promising results. In this article, we review the evidence that alterations in glutamatergic neurotransmission, especially focusing on the N‐methyl‐d ‐aspartate receptor (NMDAR) function, may be a critical causative feature of schizophrenia, how this contributes to pathologic circuit function in the brain, and how these insights are revealing whole new avenues for treatment development that could reduce treatment‐resistant symptoms, which account for persistent disability. 相似文献
993.
994.
Bryan E.K. Guevara Suhail Saleem Wan‐Ting Chen Pa‐Fan Hsiao Yu‐Hung Wu 《Journal of cutaneous pathology》2019,46(5):347-352
Lucio phenomenon is an atypical reaction of leprosy, characterized by vasculitic lesions that can mimic antiphospholipid syndrome (APS) clinically. Distinguishing the two can be difficult as antiphospholipid autoantibodies may be present in patients with leprosy. We report on a 32‐year‐old female patient presenting with a sudden onset of fever, hemorrhagic bullae, and skin necrosis on her lower legs. She was treated for APS due to the presence of antiphospholipid antibodies but had an inadequate response. A skin biopsy revealed thrombotic vasculopathy and necrotizing vasculitis associated with aggregation of foam cells in the perivascular area and subcutis, with acid‐fast bacilli in the histiocytes and blood vessel walls. Direct immunofluorescence showed IgM, C3, and fibrinogen deposition in the superficial and deep dermal blood vessels. The pathology confirmed the diagnosis of Lucio phenomenon, and appropriate therapy was given. It is essential to evaluate the patient comprehensively, including clinical, serological, and pathological aspects, to obtain the correct diagnosis. 相似文献
995.
996.
This paper reviews the published literature on a group of developmental disorders of the retina and retinal pigment epithelium which result in focal abnormalities in one or both eyes. They are often asymptomatic, found on routine examination and are generally non-progressive. Some are associated with other systemic abnormalities.Subject terms: Retinal diseases, Eye abnormalities 相似文献
997.
998.
999.
1000.
Arjenne H.M. Gussenhoven Amika S. Singh S. Theo Goverts Marten van Til Johannes R. Anema Sophia E. Kramer 《International journal of audiology》2015,54(8):507-517
Objective: A multidisciplinary vocational rehabilitation programme, the Vocational Enablement Protocol (VEP) was developed to address the specific needs of employees with hearing difficulties. In the current study we evaluated the process of implementing the VEP in audiologic care among employees with hearing impairment. Design: In conjunction with a randomized controlled trial, we collected and analysed data on seven process parameters: recruitment, reach, fidelity, dose delivered, dose received and implemented, satisfaction, and perceived benefit. Study sample: Sixty-six employees with hearing impairment participated in the VEP. The multidisciplinary team providing the VEP comprised six professionals. Results: The professionals performed the VEP according to the protocol. Of the recommendations delivered by the professionals, 31% were perceived as implemented by the employees. Compliance rate was highest for hearing-aid uptake (51%). Both employees and professionals were highly satisfied with the VEP. Participants rated good perceived benefit from it. Conclusions: Our results indicate that the VEP could be a useful treatment for employees with hearing difficulties from a process evaluation perspective. Implementation research in the audiological setting should be encouraged in order to further provide insight into parameters facilitating or hindering successful implementation of an intervention and to improve its quality and efficacy. 相似文献